Can a blood test predict who benefits from immunotherapy plus radiation?

NCT ID NCT04892849

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times

Summary

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already scheduled to receive immunotherapy (PD-1/PD-L1 inhibitors). Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if changes in a person's immune cells (measured through blood tests) can predict who will benefit most. The goal is to find better ways to personalize cancer treatment. About 200 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Radiation Oncology, Universitätsklinikum Erlangen

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.